UBS raised the firm’s price target on Pediatrix Medical (MD) to $25 from $22 and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Medical price target raised to $24 from $21 at Mizuho
- Pediatrix Shareholders Reelect Board and Approve Governance Measures
- Pediatrix Medical Group Reaffirms EBITDA Outlook on Call
- Pediatrix Medical reaffirms FY26 adjusted EBITDA view $280M-$300M
- Pediatrix Medical reports Q1 adjusted EPS 44c, consensus 38c